Company · CIK 0001674632 · SIC 3841 — Surgical & Medical Instruments & Apparatus · Nasdaq
Beta Bionics, Inc. · BBNX
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 22, 2026 SForm 4 → | Sep 23, 5:40 pm EDT | Christy JonesDirector | 6,430 | $23.00 | $147,890 | 19,564 | −24.7% | 10b5-1 |
| Sep 16, 2026 SForm 4 → | Sep 17, 4:15 pm EDT | Mark HopmanChief Commercial Officer | 30,779 | $20.13 | $619,640 | 56,479 | −35.3% | 10b5-1 |
| Sep 16, 2026 SForm 4 → | Sep 17, 4:15 pm EDT | Mike MensingerChief Product Officer | 2,650 | $22.00 | $58,300 | 177,390 | −1.47% | 10b5-1 |
| Sep 14, 2026 SForm 4 → | Sep 15, 4:15 pm EDT | Mark HopmanChief Commercial Officer | 775 | $15.52 | $12,028 | 86,382 | −0.89% | 10b5-1 |
| Sep 9, 2026 SForm 4/A → | Sep 18, 7:51 pm EDT | Mark HopmanChief Commercial Officer | 35,994 | $18.46 | $664,550 | 88,033 | −29.0% | 10b5-1 |
| Sep 9, 2026 SForm 4 → | Sep 10, 4:30 pm EDT | Mark HopmanChief Commercial Officer | 36,870 | $18.46 | $680,723 | 87,157 | −29.7% | 10b5-1 amended |
| Sep 3, 2026 SForm 4 → | Sep 4, 5:19 pm EDT | Sean SaintPresident & CEO, Director | 5,641 | $20.08 | $113,259 | 398,429 | −1.40% | 10b5-1 |
| Sep 2, 2026 SForm 4 → | Sep 3, 6:15 pm EDT | Mark HopmanChief Commercial Officer | 5,327 | $19.11 | $101,815 | 124,027 | −4.12% | |
| Sep 2, 2026 SForm 4 → | Sep 3, 6:15 pm EDT | Steven Jon RussellChief Medical Officer | 4,221 | $19.11 | $80,676 | 169,628 | −2.43% | |
| Sep 2, 2026 SForm 4 → | Sep 3, 6:15 pm EDT | Mike MensingerChief Product Officer | 4,375 | $19.11 | $83,620 | 180,040 | −2.37% | |
| Sep 2, 2026 SForm 4 → | Sep 3, 6:15 pm EDT | Stephen FeiderChief Financial Officer | 6,675 | $19.11 | $127,580 | 159,378 | −4.02% | |
| Sep 2, 2026 SForm 4 → | Sep 3, 6:15 pm EDT | Sean SaintPresident & CEO, Director | 16,867 | $19.11 | $322,381 | 404,070 | −4.01% |
Reported at this company — derivatives (options, RSUs, warrants)
No reported derivative activity in this period.